

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:19-cv-00343	Cody, Ryan	Bristol-Myers Squibb Company et al			Direct File	4/13/2020	8/27/2019
5:19-cv-00230	Abernathy, Leonard	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/31/2019
5:18-cv-00635	Abshire, Kathy	Bristol-Myers Squibb Company et al			Direct File	8/1/2019	11/30/2018
5:18-cv-00130	Adams, Jerald	Bristol-Myers Squibb Company et al	ILCD	1:18-cv-01015	CTO 1	11/3/2022	2/16/18
5:18-cv-00307	Alexander, Billy	Bristol-Myers Squibb Company et al	ALMD	3:18-cv-00394	CTO 11	5/11/2021	5/1/18
5:19-cv-00132	Alston, James	Bristol-Myers Squibb Company et al			Direct File	6/21/2019	3/29/2019
5:18-cv-00279	Anderson Jr, John	Bristol-Myers Squibb Company, et al	PAMD	3:18-cv-00752	CTO 10	11/3/2022	4/23/18
5:18-cv-00091	Asencio, Edwin	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03036	TO	11/3/2022	2/13/18
5:18-cv-00088	Atkins, Allen Sr.	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03034	TO	7/20/2020	2/13/18
5:18-cv-00305	Austin, Shelia	Bristol-Myers Squibb Company et al	LAMD	3:18-cv-00374	CTO 11	7/17/2020	5/1/18
5:18-cv-00323	Bakalyar, Diane	Bristol-Myers Squibb Company et al	TXSD	4:18-cv-01068	CTO 11	5/11/2021	5/1/18
5:18-cv-00319	Baker, Francoisce	Bristol-Myers Squibb Company et al	TXWD	1:18-cv-00284	CTO 11	5/6/2019	5/1/18
5:18-cv-00304	Banks, Minnie	Bristol-Myers Squibb Company et al	ALMD	2:18-cv-00397	CTO 11	5/12/2021	5/1/18
5:18-cv-00098	Barner, Wilma	Bristol-Myers Squibb Company et al	KYWD	5:17-cv-00180	CTO 1	11/3/2022	2/15/18
5:18-cv-00054	Barnes, Kathy	Bristol-Myers Squibb Company, et al	EDKY	2:17-cv-00124	TO	11/3/2022	2/12/18
5:19-cv-00194	Barnett, Elana	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/1/2019
5:18-cv-00505	Barrientes, Ruben	Bristol-Myers Squibb Company	GAND	3:18-cv-00082	CTO 19	11/3/2022	10/5/18
5:18-cv-00562	Becoat, Lisa	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/5/18
5:18-cv-00109	Beeler, Harvey	Bristol-Myers Squibb Company et al	INSD	4:17-cv-00207	CTO 1	8/14/2019	2/15/18
5:20-cv-00383	Bell, Toby	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	9/10/2020
5:18-cv-00350	Berry, Susan	Bristol-Myers Squibb Company et al	OKND	4:18-cv-00188	CTO 11	10/9/2020	5/3/18
5:18-cv-00343	Billington, Eddie	Bristol-Myers Squibb Company et al	TXED	6:18-cv-00160	CTO 11	11/3/2022	5/2/18
5:18-cv-00083	Binns, Earl	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03028	TO	8/1/2019	2/13/18
5:18-cv-00316	Birk, Susan	Bristol-Myers Squibb Company et al	INSD	4:18-cv-00058	CTO 11	11/3/2022	5/1/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:20-cv-00207	Biscardi, Thomas	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/19/2020
5:18-cv-00263	Bivins, Robert	Bristol-Myers Squibb Company et al	TXND	3:18-cv-00828	CTO 9	7/17/2020	4/19/18
5:18-cv-00352	Black, Margie	Bristol-Myers Squibb Company et al	OHND	1:18-cv-00762	CTO 11	7/17/2020	5/7/18
5:18-cv-00072	Boller, Neva	Bristol-Myers Squibb Company, et al	TXND	4:17-cv-00050	TO	11/3/2022	2/12/18
5:18-cv-00235	Booth, Teresa	Bristol-Myers Squibb Company et al	ARED	4:18-cv-00231	CTO 9	9/19/2019	4/18/18
5:19-cv-00153	Born, Robert	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:19-cv-00252	Branham, Jerry	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	6/19/2019
5:20-cv-00405	Breeland, Samuel W.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	9/29/2020
5:18-cv-00287	Brittain, Jerry	Bristol-Myers Squibb Company et al	OKW	5:18-cv-00283	CTO 9	11/3/2022	4/25/18
5:19-cv-00422	Brooks, David	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/21/2019
5:18-cv-00071	Brown, Bobbie	Bristol-Myers Squibb Company, et al	LAMD	3:17-cv-00039	TO	6/7/2019	2/9/18
5:18-cv-00390	Brown, Jeffrey L.	Bristol-Myers Squibb Company	OKND	4:18-cv-00190	CTO 15	5/6/2019	6/12/18
5:18-cv-00578	Brown, Perry	Bristol Meyers Squibb Company	PAED	2:18-cv-03730	CTO 21	11/3/2022	10/12/18
5:19-cv-00122	Brown, Shawntay	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/28/2019
5:18-cv-00375	Butler, James	Bristol -Myers Squibb Company	NYSD	1:18-cv-02913	CTO 14	11/3/2022	6/1/18
5:19-cv-00128	Cagle, Audrey	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:18-cv-00136	Caldwell, David	Bristol-Myers Squibb Company et al	OHND	3:18-cv-00190	CTO 1	5/6/2019	2/15/18
5:18-cv-00135	Campbell, Cheryl	Bristol-Myers Squibb Company et al	OHND	4:17-cv-02573	CTO 1	8/1/2019	2/15/18
5:18-cv-00090	Campbell, Tony	Bristol-Myers Squibb Company, et al	TNED	1:17-cv-00219	TO	11/3/2022	2/14/18
5:18-cv-00301	Cannon, Charles	Bristol-Myers Squibb Company et al	TNWD	2:18-cv-02223	CTO 11	11/3/2022	5/1/18
5:18-cv-00060	Carpenter, Donald Jr.	Bristol-Myers Squibb Company, et al	OHSD	1:17-cv-00262	TO	6/21/2019	2/12/18
5:18-cv-00333	Carter, Jennifer	Bristol-Myers Squibb Company et al	ILND	1:18-cv-02416	CTO 11	11/3/2022	5/1/18
5:18-cv-00245	Carter, Nicky	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02862	CTO 9	4/10/2020	4/19/18
5:18-cv-00119	Carter, Roy	Bristol-Myers Squibb Company et al	TXND	3:17-cv-03028	CTO 1	11/3/2022	2/15/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:19-cv-00393	Carvin, Jefferey V.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	9/25/2019
5:18-cv-00338	Caston, Michael	Bristol-Myers Squibb Company et al	ILSD	3:18-cv-00751	CTO 11	11/3/2022	5/2/18
5:18-cv-00314	Chapman, Martha	Bristol-Myers Squibb Company et al	OHSD	2:18-cv-00300	CTO 11	11/3/2022	5/1/18
5:18-cv-00064	Chester, Wrendell	Bristol-Myers Squibb Company, et al	TXSD	4:17-cv-00316	TO	12/3/2019	2/12/18
5:18-cv-00066	Christensen, Sheryle	Bristol-Myers Squibb Company, et al	IDD	1:17-cv-00321	TO	11/3/2022	2/13/18
5:19-cv-00025	Clanton, Georgia	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	1/28/2019
5:18-cv-00241	Clark, John	Bristol-Myers Squibb Company et al	OHND	3:18-cv-00715	CTO 9	11/3/2022	4/18/18
5:20-cv-00072	Coleman, Sidney	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/28/2020
5:18-cv-00143	Collins, Henry	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019
5:18-cv-00300	Corbello, Gilbert	Bristol-Myers Squibb Company et al	LAWD	2:18-cv-00461	CTO 11	11/3/2022	5/1/18
5:18-cv-00354	Couisan, Clarence	Bristol-Myers Squibb Company et al	LAED	2:18-cv-03586	CTO 11	11/3/2022	5/8/18
5:18-cv-00074	Cousins, Donielle	Bristol-Myers Squibb Company, et al	INSD	1:17-cv-02607	TO	11/3/2022	2/13/18
5:19-cv-00439	Crawford, Judy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/1/2019
5:18-cv-00267	Crear, Debbie	Bristol-Myers Squibb Company et al	TXND	3:18-cv-00826	CTO 9	5/6/2019	4/19/18
5:18-cv-00217	Curtis, Robert	Bristol-Myers Squibb Company, et al	EDKY	5:18-cv-204	CONS	11/3/2022	4/9/18
5:19-cv-00123	Daily, Deanna	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/28/2019
5:18-cv-00068	Davila, Rosa	Bristol-Myers Squibb Company, et al	TXSD	2:17-cv-00145	TO	8/14/2019	2/13/18
5:20-cv-00208	Davis, Angela F.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/19/2020
5:18-cv-00122	Davis, Billy	Bristol-Myers Squibb Company et al	TXND	4:17-cv-00888	CTO 1	11/3/2022	2/15/18
5:18-cv-00386	Davis, Mark (Sr.)	Bristol-Myers Squibb Company	NYSD	1:18-cv-02896	CTO 15	8/1/2019	6/11/18
5:19-cv-00089	Davis, Sonja	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/7/2019
5:18-cv-00089	Day, Linda	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03035	TO	11/3/2022	2/13/18
5:20-cv-00419	De La Vega, Lois Montgomery	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/7/2020
5:18-cv-00344	Delaney, Mary	Bristol-Myers Squibb Company et al	TXND	4:18-cv-00257	CTO 11	11/3/2022	5/2/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:19-cv-00461	Denmon, Elaine (Estate)	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/22/2019
5:18-cv-00337	Didericksen, Belinda	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-03008	CTO 11	11/3/2022	5/2/18
5:18-cv-00134	Dinger, William	Bristol-Myers Squibb Company et al	OHND	5:17-cv-02333	CTO 1	11/3/2022	2/15/18
5:18-cv-00100	Driver, Wayne	Bristol-Myers Squibb Company et al	COD	1:17-cv-02798	CTO 1	11/3/2022	2/15/18
5:18-cv-00341	Dunn, Helen	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-03013	CTO 11	11/3/2022	5/2/18
5:18-cv-00349	Dunn, Roberta	Bristol-Myers Squibb Company et al	OKND	4:18-cv-00187	CTO 11	11/3/2022	5/3/18
5:19-cv-00130	Dupree, Michelle	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:19-cv-00350	Elk, Marina Eagle	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	9/3/2019
5:18-cv-00114	Ellis, Allen	Bristol-Myers Squibb Company et al	MDD	1:17-cv-02974	CTO 1	4/18/2019	2/15/18
5:18-cv-00124	Epps, Jay	Bristol-Myers Squibb Company et al	SCD	4:17-cv-03297	CTO 1	11/3/2022	2/15/18
5:18-cv-00372	Ervin, Robert	Bristol-Myers Squibb Company	OKED	6:18-cv-00094	CTO 13	11/3/2022	5/30/18
5:18-cv-00262	Erwin, Bailey	Bristol-Myers Squibb Company et al	TXND	3:18-cv-00824	CTO 9	5/6/2019	4/19/18
5:20-cv-00124	Evans, Jerry Jamal for Gordon	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/27/2020
5:18-cv-00308	Ferrell, Donnie Vernon	Bristol-Myers Squibb Company et al	TNWD	1:18-cv-02225	CTO 11	11/3/2022	5/1/18
5:19-cv-00133	Ford, William	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:18-cv-00247	Forgione, Donald	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02863	CTO 9	11/3/2022	4/19/18
5:18-cv-00265	Fouse, Deanna	Bristol-Myers Squibb Company et al	TXND	3:18-cv--00825	CTO 9	6/21/2019	4/19/18
5:18-cv-00162	Freeman, Teresa	Bristol-Myers Squibb Company et al	NCMD	1:18-cv-00046	CTO 4	11/3/2022	3/2/18
5:20-cv-00073	Fyffe, Calice May	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/28/2020
5:18-cv-00240	Ganzalez-McAllister, Milagros	Bristol-Myers Squibb Company et al	MOWD	4:18-cv-00260	CTO 9	11/3/2022	4/18/18
5:18-cv-00115	Garcia, Walter	Bristol-Myers Squibb Company et al	FLMD	6:17-cv-02095	CTO 1	7/17/2020	2/15/18
5:18-cv-00257	Garrette, Lawana	Bristol-Myers Squibb Company et al	MSSD	3:18-cv-00214	CTO 9	5/11/2021	4/18/18
5:18-cv-00298	Garry, Richard	Bristol-Myers Squibb Company et al	LAWD	2:18-cv-00460	CTO 11	11/3/2022	5/1/18
5:18-cv-00132	George, Milton	Bristol-Myers Squibb Company, et al	ALMD	2:18-cv-00058	CTO 2	11/3/2022	2/15/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:19-cv-00135	Gholar, Harlon	Bristol-Myers Squibb Company et al			Direct File	9/19/2019	3/29/2019
5:20-cv-00281	Gilchrist, Kelvin	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	7/1/2020
5:18-cv-00236	Gintz, Jay	Bristol-Myers Squibb Company et al	ILSD	3:18-cv-00632	CTO 9	8/14/2019	4/18/18
5:18-cv-00105	Goforth, Margie	Bristol-Myers Squibb Company et al	ARED	4:17-cv-00736	CTO 1	11/3/2022	2/15/18
5:18-cv-00322	Gomez, Ray	Bristol-Myers Squibb Company et al	TXSD	1:18-cv-00055	CTO 11	7/17/2020	5/1/18
5:18-cv-00321	Gonzalez, Juan	Bristol-Myers Squibb Company et al	TXWD	1:18-cv-00286	CTO 11	11/3/2022	5/1/18
5:18-cv-00255	Gooch, Oswald	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02917	CTO 9	4/10/2020	4/19/18
5:18-cv-00271	Gordon, Harry	Bristol-Myers Squibb Company et al	TXSD	2:18-cv-00092	CTO 9	11/3/2022	4/20/18
5:18-cv-00056	Gore, Audrey	Bristol-Myers Squibb Company, et al	SCD	4:17-cv-01695	TO	11/3/2022	2/12/18
5:18-cv-00369	Gosner, Susan	Bristol-Myers Squibb Company	AZD	4:18-cv-00169	CTO 13	4/10/2020	5/29/18
5:18-cv-00131	Green, Ethel	Bristol-Myers Squibb Company et al	GAND	1:17-cv-04342	CTO 1	11/3/2022	2/16/18
5:18-cv-00086	Green, H.B.	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03032	TO	7/20/2020	2/13/18
5:19-cv-00155	Greer, Nancy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:19-cv-00463	Griffith, Mackie J.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/22/2019
5:18-cv-00167	Grimes, Harry	Bristol-Myers Squibb Company et al	PAED	2:18-cv-00263	CTO 4	11/3/2022	3/6/18
5:19-cv-00161	Haggar, Vanessa D.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/8/2019
5:18-cv-00347	Haley, Carolyn	Bristol-Myers Squibb Company et al	OKND	4:18-cv-00185	CTO 11	11/3/2022	5/3/18
5:18-cv-00571	Hampton, Roxie	Bristol Meyers Squibb Company	PAED	2:18-cv-03731	CTO 21	11/3/2022	10/11/18
5:18-cv-00270	Hardin, Raymond	Bristol-Myers Squibb Company et al	INSD	4:18-cv-00055	CTO 9	11/3/2022	4/20/18
5:19-cv-00055	Harding, Walter	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/18/2019
5:18-cv-00112	Hardy, Angela	Bristol-Myers Squibb Company et al	ALND	2:17-cv-02024	CTO 1	5/11/2021	2/15/18
5:18-cv-00246	Harrell, Barbara	Bristol-Myers Squibb Company et al	MSSD	3:18-cv-00202	CTO 9	11/3/2022	4/18/18
5:19-cv-00140	Harrington, Eli	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00596	Harris, Billy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/5/2018
5:19-cv-00414	Harris, Billy	Bristol-Myers Squibb Company et al			Direct File	4/10/2020	10/8/2019
5:18-cv-00108	Harris, Willie	Bristol-Myers Squibb Company et al	GAND	1:17-cv-04934	CTO 1	11/3/2022	2/15/18
5:18-cv-00272	Hasan, Sabir	Bristol-Myers Squibb Company et al	TXND	7:18-cv-00045	CTO 9	6/7/2019	4/20/18
5:18-cv-00253	Havice, Michael	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02914	CTO 9	11/3/2022	4/19/18
5:18-cv-00145	Hayes, Alphonso	Bristol-Myers Squibb Company et al	GAND	3:17-cv-00157	CTO 1	11/3/2022	2/20/18
5:18-cv-00297	Helire, Donald	Bristol-Myers Squibb Company et al	INND	1:18-cv-00081	CTO 11	11/3/2022	5/1/18
5:18-cv-00303	Herbert, Olivier	Bristol-Myers Squibb Company et al	LAWD	2:18-cv-00462	CTO 11	5/12/2021	5/1/18
5:19-cv-00436	Herrera, Mable	Bristol-Myers Squibb Company et al			Direct File	5/11/2021	10/30/2019
5:18-cv-00340	Hightower, William	Bristol-Myers Squibb Company et al	TXED	6:18-cv-00159	CTO 11	5/6/2019	5/2/18
5:18-cv-00357	Hocker, Christopher	Bristol-Myers Squibb Company et al	TNMD	3:18-cv-00341	CTO 11	5/12/2021	5/11/18
5:18-cv-00070	Holland, Anita	Bristol-Myers Squibb Company, et al	NCMD	1:17-cv-00710	TO	11/3/2022	2/9/18
5:18-cv-00113	Holmes, Mattie	Astrazeneca Pharmaceuticals LP, et al	FLSD	1:17-cv-24379	CTO 1	8/1/2019	2/15/18
5:18-cv-00318	Hopkins, Bonnie	Bristol-Myers Squibb Company et al	ILND	1:18-cv-02414	CTO 11	5/11/2021	5/1/18
5:19-cv-00095	Horne, Diane	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/8/2019
5:19-cv-00138	Hosey, Travis	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/2/2019
5:18-cv-00325	Howard, Jr. Howard	Bristol-Myers Squibb Company et al	ALSD	1:18-cv-00159	CTO 11	11/3/2022	5/1/18
5:19-cv-00139	Hudson, Joe	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/2/2019
5:19-cv-00142	Hudson, Roy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019
5:18-cv-00299	Huff, Addie	Bristol-Myers Squibb Company et al	AZD	2:18-cv-01036	CTO 11	6/21/2019	5/1/18
5:18-cv-00069	Hulbert, Carl	Bristol-Myers Squibb Company, et al	OKED	6:17-cv-00327	TO	5/6/2016	2/9/18
5:18-cv-00334	Humphrey, Cynthia	Bristol-Myers Squibb Company et al	GAMD	1:18-cv-00075	CTO 11	11/3/2022	5/2/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
 Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00140	Hunt, John Jr.	Bristol-Myers Squibb Co et al	GAMD	5:14-cv-00419	CTO 3	3/6/2019	2/20/18
5:20-cv-00141	Hunter, James	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2020
5:19-cv-00156	Irvan, Tyrone	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/5/2019
5:18-cv-00087	Ishman, Georgia	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03033	TO	11/3/2022	2/13/18
5:18-cv-00335	Jackson, Donald	Bristol-Myers Squibb Company et al	TXWD	5:18-cv-00304	CTO 11	11/3/2022	5/2/18
5:18-cv-00116	Jackson, Sherman	Bristol-Myers Squibb Company et al	TNWD	2:17-cv-02808	CTO 1	11/3/2022	2/15/18
5:18-cv-00286	Jarman, Carl	Bristol-Myers Squibb Company et al	WIED	2:18-cv-00511	CTO 9	4/18/2019	4/24/18
5:19-cv-00144	Johnson, Angelo	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019
5:18-cv-00139	Johnson, Derrell	Bristol-Myers Squibb Co et al	LAWD	6:18-cv-00120	CTO 3	11/3/2022	2/20/18
5:18-cv-00107	Johnson, Maisha	Bristol-Myers Squibb Company et al	NJD	3:17-cv-04533	CTO 1	11/3/2022	2/15/18
5:18-cv-00081	Johnson, Norman	Bristol-Myers Squibb Company, et al	GAND	1:17-cv-02916	TO	11/3/2022	2/13/18
5:18-cv-00329	Johnson, Wanda	Bristol-Myers Squibb Company et al	ILND	3:18-cv-50117	CTO 11	7/17/2020	5/1/18
5:20-cv-00236	Johnston, Mark	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	6/2/2020
5:18-cv-00154	Jones, Mark	Bristol-Myers Squibb Company et al	LAED	2:17-cv-12986	CTO 1	11/3/2022	2/23/18
5:18-cv-00258	Jones, Milton	Bristol-Myers Squibb Company et al	TXSD	4:18-cv-00969	CTO 9	11/3/2022	4/19/18
5:19-cv-00071	Karitenos, Louis	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/26/2019
5:18-cv-00244	Kee, Nancy	Bristol-Myers Squibb Company et al	KYWD	5:18-cv-00049	CTO 9	11/3/2022	4/18/18
5:19-cv-00125	Kelly, Sara	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/28/2019
5:18-cv-00242	Key, John	Bristol-Myers Squibb Company et al	NCMD	1:18-cv-00265	CTO 9	4/18/2019	4/18/18
5:18-cv-00313	King, Charles	Bristol-Myers Squibb Company et al	GAND	1:18-cv-01448	CTO 11	6/21/2019	5/1/18
5:18-cv-00099	Lacy, Vicki	Bristol-Myers Squibb Company et al	ALND	7:17-cv-02056	CTO 1	11/3/2022	2/15/18
5:18-cv-00170	Lawrence, Diana	Bristol Myers Squibb Company et al	OHSD	2:18-cv-00165	CTO 6	11/3/2022	3/8/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00336	Leary, Elmer	Bristol-Myers Squibb Company et al	NJD	1:18-cv-05409	CTO 11	11/3/2022	5/2/18
5:18-cv-00320	LeBlanc, Kevin	Bristol-Myers Squibb Company et al	LAMD	3:18-cv-00375	CTO 11	11/3/2022	5/1/18
5:18-cv-00073	Letell, Ronald	Bristol-Myers Squibb Company, et al	LAWD	2:17-cv-00553	TO	11/3/2022	2/9/18
5:19-cv-00401	Liles, Patricia	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/1/2019
5:18-cv-00249	Loggan, Catina	Bristol-Myers Squibb Company et al	MSND	1:18-cv-00061	CTO 9	8/14/2019	4/18/18
5:18-cv-00330	Lucas, Linda	Bristol-Myers Squibb Company et al	GAMD	5:18-cv-00113	CTO 11	11/3/2022	5/1/18
5:18-cv-00127	Lyles, Lynda	Bristol-Myers Squibb Company et al	MOWD	2:18-cv-04001	CTO 1	11/3/2022	2/15/18
5:18-cv-00120	Lynn, Don	Bristol-Myers Squibb Company et al	TXND	5:17-cv-00278	CTO 1	11/3/2022	2/15/18
5:20-cv-00148	Mack, Marie Ann	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/10/2020
5:18-cv-00310	Mann, James	Bristol-Myers Squibb Company et al	ALND	3:18-cv-00541	CTO 11	6/21/2019	5/1/18
5:19-cv-00219	Mann, Nada	Bristol-Myers Squibb Company et al			Direct File	12/3/2019	5/20/2019
5:18-cv-00356	Marcum, Phyllis	Bristol-Myers Squibb Company	OHSD	2:18-cv-00407	CTO 12	11/3/2022	5/10/18
5:18-cv-00095	Martin, Michael	Bristol-Myers Squibb Company, et al	CAND	3:17-cv-00661	TO	4/2/2021	2/14/18
5:18-cv-00295	Martin, Terry	Bristol-Myers Squibb Company et al	KYWD	3:18-cv-00207	CTO 11	7/17/2020	5/1/18
5:18-cv-00370	Martin, Violet	Bristol-Myers Squibb Company	WVND	3:18-cv-00045	CTO 13	5/11/2021	5/29/18
5:18-cv-00104	Mask, Jason	Bristol-Myers Squibb Company et al	FLND	3:17-cv-00860	CTO 1	11/3/2022	2/15/18
5:19-cv-00126	Mason, Thomas	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/28/2019
5:18-cv-00324	Matthews, Larry	Bristol-Myers Squibb Company et al	TXSD	4:18-cv-01070	CTO 11	5/6/2019	5/1/18
5:18-cv-00252	Maurras, Druella	Bristol-Myers Squibb Company et al	MSSD	3:18-cv-00201	CTO 9	11/3/2022	4/18/18
5:19-cv--00154	Mays, Betty	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:18-cv-00085	McAfee, Darryl	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03030	TO	11/3/2022	2/13/18
5:18-cv-00137	McCall, Randall	Bristol-Myers Squibb Company et al	OKED	6:17-cv-00409	CTO 1	9/19/2019	2/16/18



MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00155	McCay, Sharon	Bristol-Myers Squibb Co et al	PAWD	3:18-cv-00021	CTO 3	11/3/2022	2/23/18
5:19-cv-00190	McConnell, Curtis B.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/30/2019
5:18-cv-00450	McCugh, Cyndy	Bristol-Myers Squibb Company	NYSD	1:18-cv-02893	CTO 17	8/1/2019	7/11/18
5:18-cv-00331	McGhee, Roy	Bristol-Myers Squibb Company et al	GAMD	5:18-cv-00114	CTO 11	11/3/2022	5/1/18
5:19-cv-00221	McGhgy, Estate of Theodore	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/21/2019
5:18-cv-00302	McKinley, Marcia	Bristol-Myers Squibb Company et al	AZD	2:18-cv-01039	CTO 11	11/3/2022	5/1/18
5:19-cv-00145	McLean, Lewis	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019
5:18-cv-00126	Medley, Therese	Bristol-Myers Squibb Company et al	UTD	1:17-cv-00179	CTO 1	5/6/2019	2/15/18
5:18-cv-00144	Merritt, Richard	Bristol-Myers Squibb Company et al	GAND	3:17-cv-00156	CTO 1	6/21/2018	2/20/18
5:18-cv-00449	Miears, Kelley	Bristol-Myers Squibb Company	NYSD	1:18-cv-02744	CTO 17	11/3/2022	7/11/18
5:18-cv-00063	Miller, Michael	Bristol-Myers Squibb Company, et al	INND	1:17-cv-00330	TO	11/3/2022	2/13/18
5:18-cv-00248	Mills, Veryl	Bristol-Myers Squibb Company et al	ILND	3:18-cv-50110	CTO 9	11/3/2022	4/18/18
5:18-cv-00082	Mitchell, Amy	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03026	TO	11/3/2022	2/13/18
5:18-cv-00281	Mitchell, Jean	Bristol-Myers Squibb Company et al	PAMD	3:18-cv-00733	CTO 10	11/3/2022	4/23/18
5:18-cv-00342	Moody, Michael	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-03019	CTO 11	11/3/2022	5/2/18
5:18-cv-00147	Moore, David	Bristol-Myers Squibb Co et al	IASD	1:17-cv-00036	CTO 3	11/3/2022	2/20/18
5:20-cv-00007	Moran, John	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	1/9/2020
5:18-cv-00648	Moton, Georgia	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	12/17/2018
5:18-cv-00570	Mounteer, Elke	Bristol Meyers Squibb Company	NJD	3:18-cv-13904	CTO 21	7/20/2020	10/10/18
5:18-cv-00348	Nail, Shirley	Bristol-Myers Squibb Company et al	OKND	4:18-cv-00186	CTO 11	11/3/2022	5/3/18
5:18-cv-00110	Nance, Pixie	Bristol-Myers Squibb Company et al	GAND	3:17-cv-00155	CTO 1	11/3/2022	2/15/18
5:20-cv-00340	Neal, Eugene	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	8/5/2020

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
 Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:19-cv-00462	Negron, Myrna	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/22/2019
5:18-cv-00448	Nelson, Cathy	Bristol-Myers Squibb Company	NYSD	1:18-cv-02643	CTO 17	11/3/2022	7/11/18
5:18-cv-00164	Nesselrodt, Patsy	Bristol-Myers Squibb Company et al	VAWD	3:18-cv-00012	CTO 5	4/18/2019	3/6/18
5:19-cv-00223	Newton, Rual Gene	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/23/2019
5:18-cv-00634	Nicholas, Sonia	Bristol-Myers Squibb Company, et al	NYSD	1:18-cv-09406	CTO 22	11/3/2022	11/30/2018
5:19-cv-00068	North, Stuart J.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/25/2019
5:18-cv-00243	Orschel, Katherine	Astrazeneca LP, et al	NYSD	1:18-cv-02860	CTO 9	11/3/2022	4/19/18
5:18-cv-00315	Ortega, Ceasar	Bristol-Myers Squibb Company et al	ILND	1:18-cv-02415	CTO 11	5/12/2021	5/1/18
5:19-cv-00173	O'Toole, Nancy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/22/2019
5:19-cv-00218	Parker, Grady	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/20/2019
5:18-cv-00223	Parks, Jeff	Bristol-Myers Squibb Company, et al	IASD	3:18-cv-00031	CTO 8	11/3/2022	4/13/18
5:20-cv-00330	Patton, Evelyn	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	7/29/2020
5:18-cv-00239	Payne, Kimberly	Bristol-Myers Squibb Company et al	MOWD	4:18-cv-00259	CTO 9	11/3/2022	4/18/18
5:18-cv-00055	Peoples, Lisa	Bristol-Myers Squibb Company, et al	ALND	5:17-cv-00101	TO	11/3/2022	2/12/18
5:18-cv-00234	Peoples, John	Bristol-Myers Squibb Company et al	AZD	4:18-cv-00172	CTO 9	11/3/2022	4/18/18
5:19-cv-00091	Perkins, Dean	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/7/2019
5:19-cv-00231	Perry, Wayne	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/31/2019
5:19-cv-00302	Phillips, Mary	Bristol-Myers Squibb Company et al			Direct File	8/4/2022	7/30/2019
5:20-cv-00206	Poole, Nancy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/19/2020
5:19-cv-00141	Ragsdale, Early	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/3/2019
5:19-cv-00070	Rankow, Valerie	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/26/2019
5:19-cv-00090	Ray, Floreida	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/7/2019

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00345	Ray, Hank	Bristol-Myers Squibb Company et al	TXWD	7:18-cv-00061	CTO 11	11/3/2022	5/2/18
5:18-cv-00080	Reeves, Larry et al	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03024	TO	11/3/2022	2/13/18
5:18-cv-00077	Reid, Patricia	Bristol-Myers Squibb Company, et al	GAND	1:17-cv-01503	TO	11/3/2022	2/13/18
5:18-cv-00355	Rimkus, Richard	Bristol-Myers Squibb Company et al	LAED	2:18-cv-03589	CTO 11	11/3/2022	5/8/18
5:19-cv-00127	Ritz, David	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/28/2019
5:19-cv-00227	Robinson, Rhoda	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/28/2019
5:20-cv-00143	Roseboro, Christopher	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/6/2020
5:19-cv-00403	Rosenbaum, Lloyd	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/1/2019
5:18-cv-00121	Rosencranse, Robert	Bristol-Myers Squibb Company et al	TXND	5:17-cv-00253	CTO 1	11/3/2022	2/15/18
5:18-cv-00150	Ross, Gregory	Bristol-Myers Squibb Company, et al	LAED	2:17-cv-00443	TO	11/3/2022	2/22/18
5:18-cv-00250	Rouse, Allen	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02866	CTO 9	11/3/2022	4/19/18
5:18-cv-00256	Royal, Hubert Allen	Bristol-Myers Squibb Company et al	NCED	7:18-cv-00052	CTO 9	11/3/2022	4/19/18
5:18-cv-00579	Rundell, Marian	Bristol Meyers Squibb Company	TXED	6:18-cv-00463	CTO 21	11/3/2022	10/12/18
5:19-cv-00232	Samuels, Ernestine	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	5/31/2019
5:18-cv-00133	Sandoval, Yvonne	Bristol-Myers Squibb Company et al	LAWD	6:17-cv-01501	CTO 1	6/21/2018	2/15/18
5:19-cv-00131	Santiago, Orlando	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:19-cv-00092	Schwartz, Norman	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/7/2019
5:19-cv-00076	Scott, Author W.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/27/2019
5:19-cv-00169	Scott, Leroy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/16/2019
5:18-cv-00092	Sechler, April et al	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03037	TO	7/20/2020	2/13/18
5:18-cv-00576	Serpa, Jose	Bristol Meyers Squibb Company	PAED	2:18-cv-03729	CTO 21	10/9/2020	10/12/18
5:18-cv-00065	Settle, Susan et al	Bristol-Myers Squibb Company, et al	AZD	2:17-cv-01269	TO	11/3/2022	2/12/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00510	Sexton, Wilma J.	Bristol-Myers Squibb, Co., Inc	KYED	7:18-cv-00090	CONS	11/3/2022	8/29/18
5:19-cv-00398	Shannon, Danna	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	9/26/2019
5:20-cv-00153	Sharp, Gale	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/15/2020
5:19-cv-00078	Sharp, Thelma J.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	2/28/2019
5:19-cv-00166	Shepard, Daphine	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/12/2019
5:18-cv-00374	Sheppard , Tommy Lee	Bristol-Myers Squibb Company	OKED	6:18-cv-00092	CTO 13	11/3/2022	5/30/18
5:18-cv-00339	Sheppard, Calvin	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-03009	CTO 11	11/3/2022	5/2/18
5:18-cv-00266	Sheppard, Janiet	Bristol-Myers Squibb Company et al	TXND	3:18-cv-00827	CTO 9	11/3/2022	4/19/18
5:19-cv-00023	Sherill, Martha	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	1/28/2019
5:18-cv-00117	Silvers, Cleotha	Bristol-Myers Squibb Company et al	TNWD	2:17-cv-02810	CTO 1	3/6/2019	2/15/18
5:18-cv-00598	Singletery, Billy Jean	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	11/5/2018
5:18-cv-00237	Slaton, Larry	Bristol-Myers Squibb Company et al	GASD	1:18-cv-00060	CTO 9	11/3/2022	4/18/18
5:18-cv-00146	Slaughter, Vannessa	Bristol-Myers Squibb Company et al	TXSD	4:17-cv-03321	CTO 1	12/3/2019	2/20/18
5:18-cv-00285	Smith, Gary	Bristol-Myers Squibb Company et al	WAED	1:18-cv-03049	CTO 9	11/3/2022	4/18/18
5:18-cv-00317	Smith, Mary	Bristol-Myers Squibb Company et al	ALND	7:18-cv-00536	CTO 11	6/21/2019	5/1/18
5:19-cv-00146	Smith, Ulrich	Bristol-Myers Squibb Company et al			Direct File	10/9/2020	4/3/2019
5:18-cv-00259	Sparkman, Mary	Bristol-Myers Squibb Company et al	TXSD	4:18-cv-00971	CTO 9	11/3/2022	4/19/18
5:19-cv-00129	Spearman, Peggy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:18-cv-00148	Speights, Lester	Bristol-Myers Squibb Company, et al	LAED	2:17-cv-07884	TO	11/3/2022	2/21/18
5:18-cv-00219	Spicer, Alberta	Bristol-Myers Squibb Company, et al	EDKY	5:18-cv-00213	CONS	11/3/2022	4/9/18
5:18-cv-00368	Sproule, Johann A.	Bristol-Myers Squibb Company	AZD	4:18-cv-00168	CTO 13	12/3/2019	5/29/18
5:18-cv-00111	Stacy, Jimmy	Bristol-Myers Squibb Company et al	MSND	1:17-cv-00207	CTO 1	11/3/2022	2/15/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00268	Stewart, Lori	Bristol-Myers Squibb Company et al	CAED	2:18-cv-00680	CTO 9	11/3/2022	4/20/18
5:19-cv-00147	Strange, Peggy	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:18-cv-00572	Sturgell, Gary	Bristol Meyers Squibb Company	PAED	2:18-cv-03732	CTO 21	11/3/2022	10/11/18
5:19-cv-00149	Sukhoo, Binwattie	Bristol-Myers Squibb Company et al			Direct File	5/12/2021	4/4/2019
5:19-cv-00148	Sweeney, Carolyn	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:18-cv-00084	Talton, Gail	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-03029	TO	8/1/2019	2/13/18
5:18-cv-00151	Taylor, Bobby	Bristol-Myers Squibb Company, et al	KYED	0:17-cv-00131	CONS	11/3/2022	2/22/18
5:18-cv-00053	Taylor, David	Bristol-Myers Squibb Company, et al	KYED	5:16-cv-00260	TO	11/3/2022	2/12/18
5:18-cv-00180	Telles, Raul	Bristol-Myers Squibb Company, et al	TXWD	3:18-cv-00070	CTO 7	11/3/2022	3/14/18
5:18-cv-00309	Terrell, Cathy	Bristol-Myers Squibb Company et al	GAND	1:18-cv-01447	CTO 11	5/6/2019	5/1/18
5:19-cv-00150	Thompson, Rhonda	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:19-cv-00204	Tincher, Larry	Bristol-Myers Squibb Company et al			Direct File	7/20/2020	5/8/2019
5:18-cv-00260	Trapp, Ernest et al	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02955	CTO 9	11/3/2022	4/19/18
5:18-cv-00062	Tucker, Cloyd	Bristol-Myers Squibb Company, et al	WDKY	3:17-cv-00268	TO	11/3/2022	2/12/18
5:19-cv-00499	Tugger, Vickie	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	12/23/2019
5:18-cv-00078	Turner, Cynthia	Bristol-Myers Squibb Company, et al	GAND	1:17-cv-02782	TO	11/3/2022	2/13/18
5:18-cv-00128	Turner, Dennis	Bristol-Myers Squibb Company et al	MOED	4:17-cv-02867	CTO 1	11/3/2022	2/15/18
5:18-cv-00332	Underwood, Debra	Bristol-Myers Squibb Company et al	TNED	3:18-cv-00144	CTO 11	5/11/2021	5/2/18
5:18-cv-00218	Utterback, Patrick	Bristol-Myers Squibb Company, et al	EDKY	5:18-cv-00205	CONS	4/22/2019	4/9/18
5:18-cv-00057	Vallentine, Steven	Bristol-Myers Squibb Company, et al	ALMD	3:17-cv-00265	TO	11/3/2022	2/12/18
5:18-cv-00569	Vasquez, Deborah	Astrazeneca Pharmaceuticals LP	NJD	3:18-cv-13461	CTO 21	7/20/2020	10/10/18
5:18-cv-00101	Veloria, Michael	Bristol-Myers Squibb Company et al	ARWD	3:17-cv-03110	CTO 1	11/3/2022	2/15/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00238	Walz, James	Bristol-Myers Squibb Company et al	GAND	1:18-cv-01292	CTO 9	11/3/2022	4/18/18
5:18-cv-00067	Ware, Charles	Bristol-Myers Squibb Company, et al	TXED	1:17-cv-00111	TO	11/3/2022	2/12/18
5:18-cv-00311	Ware, Linda	Bristol-Myers Squibb Company et al	OKWD	5:18-cv-00302	CTO 11	7/17/2020	5/1/18
5:18-cv-00254	Waterman, Timothy	Bristol-Myers Squibb Company et al	NYSD	1:18-cv-02915	CTO 9	4/10/2020	4/19/18
5:18-cv-00394	Watts, Alice	Bristol-Myers Squibb Company	TXND	3:17-cv-01400	CTO 16	11/3/2022	6/13/18
5:19-cv-00151	Wendricks, Anthony	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:18-cv-00373	Whiteside, Shirley	Bristol-Myers Squibb Company	WVSD	2:18-cv-00500	CTO 13	11/3/2022	5/30/18
5:19-cv-00152	Wigginton, John	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	4/4/2019
5:18-cv-00061	Wilcox, Nichole	Bristol-Myers Squibb Company, et al	TNMD	3:17-cv-01202	TO	1/17/2020	2/12/18
5:19-cv-00112	Wilkerson, Sullivan	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/20/2019
5:19-cv-00287	Wilkins, James	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	7/19/2019
5:18-cv-00094	Williams, Carolyn et al	Astrazeneca Pharmaceuticals LP, et al	CAND	3:16-cv-01752	TO	11/3/2022	2/14/18
5:20-cv-00247	Williams, Larry O.	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	6/8/2020
5:18-cv-00106	Williams, Robert	Bristol-Myers Squibb Company et al	NJD	3:17-cv-03031	CTO 1	7/17/2020	2/15/18
5:19-cv-00026	Williams, Rose	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	1/28/2019
5:18-cv-00496	Williams, Wiley Jr.	Bristol-Myers Squibb Company	GAND	3:18-cv-00082	CTO 18	11/3/2022	8/16/18
5:18-cv-00326	Williams, William E.	Bristol-Myers Squibb Company et al	ALSD	2:18-cv-00160	CTO 11	11/3/2022	5/1/18
5:18-cv-00554	Wilson, Jean	Bristol Myers Squibb Co., Inc.	MOWD	5:18-cv-06140	CTO 20	11/3/2022	10/1/18
5:19-cv-00272	Wilson, Shirley	Bristol-Myers Squibb Company et al			Direct File	5/11/2021	7/8/2019
5:18-cv-00129	Winborne, Audrie	Bristol-Myers Squibb Company et al	LAWD	3:17-cv-01535	CTO 1	11/3/2022	2/15/18
5:18-cv-00123	Winkle, Michael	Bristol-Myers Squibb Company et al	SCD	2:17-cv-03167	CTO 1	11/3/2022	2/15/18
5:18-cv-00233	Wood, Charles	Bristol-Myers Squibb Company et al	MOWD	4:18--cv-00258	CTO 9	11/3/2022	4/18/18

MDL 2809 IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability  
 Updated 11/4/2022

<b>EDKY #</b>	<b>Plaintiff</b>	<b>Defendant</b>	<b>Origin District</b>	<b>Origin Case</b>	<b>CTO</b>	<b>Term Date</b>	<b>Date Rec'd</b>
5:18-cv-00269	Woodruff, Barbara	Bristol-Myers Squibb Company et al	INSD	1:18-cv-00984	CTO 9	11/3/2022	4/20/18
5:18-cv-00102	Woods, Catherine	Bristol-Myers Squibb Company et al	NJD	3:17-cv-03027	CTO 1	8/1/2019	2/15/18
5:18-cv-00118	Word, Patricia	Bristol-Myers Squibb Company et al	TNWD	2:17-cv-02812	CTO 1	11/3/2022	2/15/18
5:19-cv-00134	Wright, Linda	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	3/29/2019
5:18-cv-00141	Yaa, Samuel	Bristol-Myers Squibb Co et al	INSD	1:17-cv-04745	CTO 3	4/13/2020	2/20/18
5:18-cv-00312	Ybarra, Guadalupe	Bristol-Myers Squibb Company et al	TXND	5:18-cv-00094	CTO 11	11/3/2022	5/1/18
5:18-cv-00079	York, Robbie	Bristol-Myers Squibb Company, et al	GAND	1:17-cv-02915	TO	11/3/2022	2/13/18
5:18-cv-00328	Young, Jacqueline	Bristol-Myers Squibb Company et al	ALSD	2:18-cv-00161	CTO 11	11/3/2022	5/1/18
5:18-cv-00076	Young, Randolph	Bristol-Myers Squibb Company, et al	NJD	3:17-cv-00347	TO	11/3/2022	2/13/18
5:18-cv-00568	Young, Victor	Bristol Meyers Squibb Company	NJD	3:18-cv-09273	CTO 21	11/3/2022	10/10/18
5:20-cv-00438	Zamarrapi, Demetrio	Bristol-Myers Squibb Company et al			Direct File	11/3/2022	10/23/2020